Recently, the stocks of Indian pharmaceutical manufacturers experienced a significant downturn. The catalyst for this decline was a statement by U.S. President Donald Trump, indicating that tariffs on pharmaceutical products are still under review. This announcement led to notable shifts in the stock market, particularly affecting the pharmaceutical sector in India.